Ultragenyx Pharmaceutical
NasdaqGS:RARE Community- 1 Narratives written by author
- 0 Comments on narratives written by author
- 2 Fair Values set on narratives written by author
AN
Consensus Narrative from 19 Analysts
FDA Progress Will Accelerate Approval Of UX111 And UX143 In 2025
Key Takeaways Global expansion and gene therapy product approvals are positioned to significantly enhance revenue streams and overall earnings. Strategic focus on cost management and operational investments aims for GAAP profitability, stabilizing margins and earnings by 2027.
View narrativeUS$89.53
FV
56.8% undervalued intrinsic discount29.76%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
4 days ago author updated this narrative